X4 Pharmaceuticals Inc
$ 4.29
3.62%
17 Apr - close price
- Market Cap 390,046,000 USD
- Current Price $ 4.29
- High / Low $ 4.38 / 4.19
- Stock P/E N/A
- Book Value 2.05
- EPS -1.87
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.23 %
- ROE -0.76 %
- 52 Week High 6.63
- 52 Week Low 1.35
About
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of new therapies for the treatment of back diseases. The company is headquartered in Boston, Massachusetts.
Analyst Target Price
$11.67
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-17 | 2025-11-05 | 2025-08-08 | 2025-05-05 | 2025-03-19 | 2024-11-13 | 2024-08-08 | 2024-05-07 | 2024-03-21 | 2023-11-09 | 2023-08-10 | 2023-05-04 |
| Reported EPS | -0.22 | -0.69 | -3.47 | 0.04 | -0.2 | -0.18 | -0.07 | -0.26 | -0.1 | -0.01 | -0.33 | -0.16 |
| Estimated EPS | -0.3475 | -0.125 | -0.0883 | -3.75 | -0.1575 | -0.17 | 0.01 | -0.16 | -0.15 | -0.15 | -0.16 | -0.22 |
| Surprise | 0.1275 | -0.565 | -3.3817 | 3.79 | -0.0425 | -0.01 | -0.08 | -0.1 | 0.05 | 0.14 | -0.17 | 0.06 |
| Surprise Percentage | 36.6906% | -452% | -3829.7848% | 101.0667% | -26.9841% | -5.8824% | -800% | -62.5% | 33.3333% | 93.3333% | -106.25% | 27.2727% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.2 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: XFOR
2026-04-16 08:40:30
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) has received an average "Hold" recommendation from brokerages, with an average 12-month price target of $8.50. Despite beating earnings and revenue estimates in its latest quarter, the company remains unprofitable, and analysts forecast a negative EPS for the current fiscal year. Institutional investors hold a significant stake, with recent increases from firms like Vanguard and Bank of America, as the stock trades near $4.33.
2026-04-02 07:39:59
This page provides access to X4 Pharmaceuticals (XFOR) SEC filings, including annual reports (10-K), quarterly earnings (10-Q), material events (8-K), and insider trading forms. Stock Titan enhances these documents with AI-powered summaries to highlight key points. Recent filings detail financing activities, leadership changes, clinical program updates, and the company's financial condition including a going-concern risk warning.
2026-04-02 05:39:59
X4 Pharmaceuticals announced inducement awards granted to new employees, consisting of options to purchase 32,000 shares of common stock. These awards were made under the company's 2019 Inducement Equity Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4), to attract new talent. The options have a ten-year term, an exercise price matching the closing price on March 31, 2026, and vest over a four-year period.
2026-04-01 21:39:28
X4 Pharmaceuticals announced inducement grants in accordance with Nasdaq Listing Rule 5635(C)(4). The announcement is a brief notice from Refinitiv, indicating compliance with specific Nasdaq regulations regarding stock grants. This news is primarily of interest to investors and those monitoring XFOR's corporate governance and stock-based compensation practices.
2026-04-01 21:39:28
X4 Pharmaceuticals announced inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). The company is a clinical-stage biopharmaceutical firm focused on rare diseases, with its lead candidate, mavorixafor, targeting CXCR4 dysfunction. This news follows recent reports on their Q4 2025 earnings and a positive EU panel opinion for a WHIM Syndrome drug.
2026-04-01 20:39:28
X4 Pharmaceuticals announced inducement option awards for new employees, granting options to purchase an aggregate of 32,000 shares under its 2019 Inducement Equity Incentive Plan. The options have an exercise price of $4.13 per share, equal to the closing price on March 31, 2026, a 10-year term, and a four-year vesting schedule. These awards were approved by X4's Compensation Committee and align with Nasdaq Listing Rule 5635(c)(4).
